Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
June 20 2024 - 9:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of June 2024
Commission File Number: 001-37643
PURPLE BIOTECH LTD.
(Translation of registrant’s name into English)
4 Oppenheimer Street, Science Park, Rehovot
7670104, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
On June 19, 2024, the Tel
Aviv District Court (Economic Division) dismissed the previously disclosed lawsuit and motion to approve the lawsuit as a class action
lawsuit which was filed against us, our executive directors and certain of our present and former directors in February 2017 (the “2017
Motion”).
As
previously disclosed, in the 2017 Motion the plaintiffs alleged, among other things, that we included misleading information in our public
filings related to our former lead drug candidate, Consensi, which caused the class for which the plaintiffs were seeking recognition
an aggregate loss of approximately NIS 29 million (approximately $7.8 million).
Now,
the Court has issued its final decision in the 2017 Motion, whereby it fully dismissed the lawsuit against the defendants as well as the
motion to approve the lawsuit as a class action lawsuit. Each party will bear its own court expenses.
Incorporation by Reference
This
Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration
Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016
(Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed
with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration
Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission
on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed
with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration
Statement on Form F-3 filed with the Securities and Exchange Commission on September 16,
2019 (Registration file number 333-233795), the Registrant’s Registration Statement on Form F-1 filed with the Securities
and Exchange Commission on December 27, 2019 (Registration file number 333-235729), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-
238229), the Registrant’s Registration Statement on Form S-8 filed with the Securities
and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrant’s Registration Statements
on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration
file numbers 333-239807 and 333-233793), the Registrant’s Registration Statement on Form S-8 filed
with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107) and the Registrant’s Registration
Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769),
the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission
on December 8, 2022 (Registration file number 333-268710) and the Registrant’s Registration Statement on Form F-1 filed
with the Securities and Exchange Commission on October 30, 2023 (Registration file number 333-275216), to be a part thereof from the date
on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
June 20, 2024 |
PURPLE BIOTECH LTD. |
|
|
|
By: |
/s/ Lior Fhima |
|
|
Lior Fhima |
|
|
Chief Financial Officer |
2
Purple Biotech (NASDAQ:PPBT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Purple Biotech (NASDAQ:PPBT)
Historical Stock Chart
From Oct 2023 to Oct 2024